Biologics Safety Testing Market by 2027: Future Scope and Predictions| Estimated CAGR of 13.3%

Comments · 41 Views

The global biologics safety testing market is projected to reach USD 6.8 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 13.3% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growing developments of biologics and biosimilars, increased concerns over the cell culture contamination, and rising investments in biopharmaceutical research and development.

Request for Sample PDF Report @     https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biologics safety testing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects.

Biologics Safety Testing Market Dynamics

Drivers: Rising investment in biopharmaceutical R&D

Over the years, the prevalence of chronic diseases, such as cancer, diabetes, and neurological and cardiovascular diseases, has increased rapidly worldwide. The research and demand for various drugs, cell therapies, diagnostics, and active biological products are expected to grow due to the increasing incidence and prevalence of such diseases.

Opportunity: Increased outsourcing of biopharmaceutical activities to CROs

Contract research organizations (CROs) act as outsourcing partners for pharmaceutical & biotechnology companies and academic institutes. CROs provide several services, such as cell and virus bank characterization, genetic stability testing, raw material testing, bulk-lot release testing, final product release testing, sterility testing services, analytical services for biologics, biodistribution studies, cell-based assay services, cleaning validation studies, biorepository services, next-generation sequencing, and endotoxin determination.

Challenge: High Cost of Biologics

Biologics and biosimilars are medications made from living cells to treat various ailments such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. Biologics are extremely targeted and effective for treating various diseases.

Get an Exclusive Discount on This Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=34624144

The Asia Pacific region is the fastest growing region of the Biologics safety testing market

The Asia Pacific market is projected to witness the highest growth rate during the forecast period. Rapid growth in outsourcing preclinical, clinical, and laboratory testing services to APAC countries is expected to drive market growth during the forecast period.

Key Market Players

Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Labcorp (US) and Eurofins Scientific (Luxembourg)

Biologics Safety Testing Market TOC @ https://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

sales@marketsandmarkets.com

disclaimer
Comments